Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Pilot Study of Plasma Cell-Free DNA Fragmentomics in Gallbladder Cancer.

JHEP reports : innovation in hepatology·2026
Same author

Correction: Targeting fibroblast activation protein-α to treat renal fibrosis.

Cellular & molecular biology letters·2026
Same author

ctxR: Utilities for interacting with the CTX APIs.

NAM journal·2026
Same author

Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma.

Cytotherapy·2026
Same author

Engineering fratricide-resistant CCR4/CD7 CAR T cells with enhanced safety and persistence for T cell malignancies.

Molecular therapy. Oncology·2026
Same author

Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individuals.

The journal of allergy and clinical immunology. Global·2026

相关实验视频

Updated: Jan 10, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K

基于化学抗原受体的细胞治疗T细胞恶性瘤.

Sile Li1, Yuanxin Li1, Man Yan Hui1

  • 1Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.

Critical reviews in oncology/hematology
|November 24, 2025
PubMed
概括

化学抗原受体 (CAR) T细胞疗法对B系癌症具有前景. 然而,针对T细胞恶性瘤的CAR T细胞疗法面临着抗原共享和T细胞无形成等挑战,需要新的方法.

关键词:
收养细胞疗法采用细胞疗法.用CAR T细胞疗法进行治疗.癌症免疫疗法癌症免疫疗法临床试验临床试验是指临床试验的临床试验.血液学疾病是一种血液学疾病.在T细胞恶性瘤中.

更多相关视频

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.6K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K

相关实验视频

Last Updated: Jan 10, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.6K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K

科学领域:

  • 免疫学 免疫学 免疫学
  • 合成生物学 合成生物学
  • 在瘤学瘤学.

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法,使用单链可变片段 (scFvs) 向瘤抗原,对B系血液恶性瘤有效.
  • 对复发性或耐药性 (R/R) T 细胞恶性瘤的治疗由于抗原共享和T 细胞无形成等挑战,仍然不理想.

研究的目的:

  • 本综述探讨了针对T细胞恶性瘤的基于CAR的细胞疗法.
  • 它讨论了各种免疫效应细胞 (IEC) 和改善CAR T细胞治疗结果的策略.

主要方法:

  • 关于治疗T细胞恶性瘤的CAR T细胞疗法的当前文献的综述.
  • 探索不同的免疫效应细胞 (IECs),包括T细胞,NK细胞,NKT细胞,CIK细胞和γδ T细胞.
  • 讨论多抗原向和新兴技术.

主要成果:

  • 在治疗T细胞恶性瘤方面,CAR T细胞疗法面临重大障碍,包括兄弟杀戮和复发风险增加.
  • 输液后严重的T细胞无形成症进一步损害了免疫功能受损的患者.

结论:

  • 基于CAR的新策略,包括多种免疫效应细胞和多抗原向,对于改善T细胞恶性瘤的结果至关重要.
  • 目前正在进行的研究和临床试验旨在克服CAR T细胞治疗这些癌症的现有局限性.